Practical considerations for nonclinical safety evaluation of therapeutic monoclonal antibodies

mAbs

Volumn 1, Issue 1, 2009, Pages 2-11

  Lynch, Carmel M ^a   Hart, Bruce W ^a   Grewal, Iqbal S ^a  

^a SEATTLE GENETICS INC   (United States)

Author keywords

Biotherapeutics; Monoclonal antibodies; Nonclinical testing; Pharmacology; Therapeutics; Toxicity studies; Toxicology

Indexed keywords

BEVACIZUMAB; CD40 LIGAND MONOCLONAL ANTIBODY; CETUXIMAB; MONOCLONAL ANTIBODY; NATALIZUMAB; RITUXIMAB; TGN 1412; TRASTUZUMAB;

BINDING AFFINITY; CARCINOGEN TESTING; CLINICAL RESEARCH; CLINICAL TRIAL; CROSS REACTION; DEMYELINATING DISEASE; DOSE RESPONSE; DRUG BINDING; DRUG DOSE ESCALATION; DRUG ERUPTION; DRUG HALF LIFE; DRUG SAFETY; DRUG TARGETING; FIBRINOLYSIS; GOOD LABORATORY PRACTICE; HISTOPATHOLOGY; HUMAN; IMMUNOTOXICITY; MULTIPLE SCLEROSIS; NONHUMAN; PRACTICE GUIDELINE; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; REPRODUCTIVE TOXICITY; REVIEW; RISK ASSESSMENT; SIDE EFFECT; SPECIES COMPARISON; T LYMPHOCYTE ACTIVATION; TOXICITY TESTING; TOXICOKINETICS; TUMOR LYSIS SYNDROME; UNSPECIFIED SIDE EFFECT; VIRAL DEMYELINATING DISEASE;

ANIMALS; ANTIBODIES, MONOCLONAL; DRUG EVALUATION, PRECLINICAL; GUIDELINES AS TOPIC; HUMANS; RECOMBINANT PROTEINS;

EID: 77953667724     PISSN: 19420862     EISSN: None     Source Type: Journal    
DOI: 10.4161/mabs.1.1.7377     Document Type: Review

References (58)

1. Reichert JM, Rosensweig CJ, Faden LB, Dewitz MC. Monoclonal antibody successes in the clinic. Nat Biotechnol 2005; 23:1073-1078
2. Adams GP, Weiner LM. Monoclonal antibody therapy of cancer. Nat Biotechnol 2005; 23:1147-1157
3. Kim SJ, Park Y, Hong HJ. Antibody engineering for the development of therapeutic antibodies. Mol Cells 2005; 20:17-29.
4. Carter PJ. Potent antibody therapeutics by design. Nat Rev Immunol 2006; 6:343-357
5. Brekke OH, Sandlie I. Therapeutic antibodies for human diseases at the dawn of the twenty-first century. Nat Rev Drug Discov 2003; 2:52-62. (Pubitemid 37361624)
6. Glennie MJ, Johnson PW. Clinical trials of antibody therapy. Immunol Today 2000; 21:403-410
7. Schrama D, Reisfeld RA, Becker JC. Antibody targeted drugs as cancer therapeutics. Nat Rev Drug Discov 2006; 5:147-159
8. Hoogenboom HR. Selecting and screening recombinant antibody libraries. Nat Biotechnol 2005; 23:1105-1116 (Pubitemid 41486392)
9. Lonberg N. Human antibodies from transgenic animals. Nat Biotechnol 2005; 23:1117-1125
10. Liu XY, Pop LM, Vitetta ES. Engineering therapeutic monoclonal antibodies. Immunol Rev 2008; 222:9-27.
11. Carson KL. Flexibility - the guiding principle for antibody manufacturing. Nat Biotechnol 2005; 23:1054-1058 (Pubitemid 41486382)
12. Birch JR, Racher AJ. Antibody production. Adv Drug Deliv Rev 2006; 58:671-685
13. Cavagnaro JA, The principles of ICH S6 and the case-by-case approach. In: Cavagnaro JA, Ed. Preclinical safety evaluation of biopharmaceuticals. Hoboken, NJ: Wiely 2008; 45-65.
14. Patton A, Mullenix MC, Swanson SJ, Koren E. An acid dissociation bridging ELISA for detection of antibodies directed against therapeutic proteins in the presence of antigen. J Immunol Methods 2005; 304:189-195 (Pubitemid 41262233)
15. Moxness M, Tatarewicz S, Weeraratne D, Murakami N, Wullner D, Mytych D, et al. Immunogenicity testing by electrochemiluminescent detection for antibodies directed against therapeutic human monoclonal antibodies. Clin Chem 2005; 51:1983-1985 (Pubitemid 41368199)
16. Chapman K, Pullen N, Graham M, Ragan I. Preclinical safety testing of monoclonal antibodies: the significance of species relevance. Nat Rev Drug Discov 2007; 6:120-126 (Pubitemid 46745340)
17. Subramanyam M and Mertsching E. Selection of relevant species. In: Cavagnaro JA, Ed. Preclinical safety evaluation of biopharmaceuticals. Hoboken, NJ: Wiely 2008; 181-205.
18. Hall WC, Price-Schiavi SA, Wicks J and Rojko JL. Tissue cross-reactivity studies for monoclonal antibodies: Predictive value and use for selection of relevant animal species for toxicity testing. In: Cavagnaro JA, Ed. Preclinical safety evaluation of biopharmaceuticals. Hoboken, NJ: Wiely 2008; 207-240
19. Green MD and Hartsough M. The role of pharmacokinetics and pharmacodynamics in selecting a relevant species. In: Cavagnaro JA, Ed. Preclinical safety evaluation of biopharmaceuticals. Hoboken, NJ: Wiely 2008; 277-291
20. ICH S6. Nonclinical Safety Evaluation of Biotechnology-Derived Pharmaceuticals. www. fda.gov/cder/Guidance/1859fnl.pdf.
21. + T-cell depletion is not required. Immunol 2000; 99:287-295
22. Yocum DE, Solinger AM, Tesser J, Gluck O, Cornett M, O'Sullivan F, et al. Clinical and immunologic effects of a PRIMATIZED anti-CD4 monoclonal antibody in active rheumatoid arthritis: results of a phase I, single dose, dose escalating trial. J Rheumatol 1998; 25:1257-1262 (Pubitemid 28312339)
23. Sharma A, Davis CB, Tobia LA, Kwok DC, Tucci MG, Gore ER, et al. Comparative pharmacodynamics of keliximab and clenoliximab in transgenic mice bearing human CD4. J Pharmacol Exp Ther 2000; 293:33-41. (Pubitemid 30180920)
24. Clarke J, Leach W, Pippig S, Joshi A, Wu B, House R, Beyer J. Evaluation of a surrogate antibody for preclinical safety testing of an anti-CD11a monoclonal antibody. Regul Toxicol Pharmacol 2004; 40:219-226 (Pubitemid 39531303)
25. Robert F, Ezekiel MP, Spencer SA, Meredith RF, Bonner JA, Khazaeli MB, et al. Phase I study of anti-epidermal growth factor receptor antibody cetuximab in combination with radiation therapy in patients with advanced head and neck cancer. J Clin Oncol 2001; 19:3234-3243 (Pubitemid 32591441)
26. Herbst RS, Langer CJ. Epidermal growth factor receptors as a target for cancer treatment: the emerging role of IMC-C225 in the treatment of lung and head and neck cancers. Semin Oncol 2002; 29:27-36. (Pubitemid 34226516)
27. Sidiropoulos PI, Boumpas DT. Lessons learned from anti-CD40L treatment in systemic lupus erythematosus patients. Lupus 2004; 13:391-397 (Pubitemid 38788502)
28. Ewer MS, O'Shaughnessy JA. Cardiac toxicity of trastuzumab-related regimens in HER2- overexpressing breast cancer. Clin Breast Cancer 2007; 7:600-607 (Pubitemid 47028508)
29. Byrd JC, Waselenko JK, Maneatis TJ, Murphy T, Ward FT, Monahan BP, et al. Rituximab therapy in hematologic malignancy patients with circulating blood tumor cells: association with increased infusion-related side effects and rapid blood tumor clearance. J Clin Oncol 1999; 17:791-795 (Pubitemid 29109307)
30. Phan GQ, Yang JC, Sherry RM, Hwu P, Topalian SL, Schwartzentruber DJ, et al. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci USA 2003; 100:8372-8377 (Pubitemid 36842552)
31. Roodhart JM, Langenberg MH, Witteveen E, Voest EE. The molecular basis of class side effects due to treatment with inhibitors of the VEGF/VEGFR pathway. Curr Clin Pharmacol 2008; 3:132-143
32. Scott CT. The problem with potency. Nat Biotechnol 2005; 23:1037-1039
33. Berger JR, Koralnik IJ. Progressive multifocal leukoencephalopathy and natalizumab - unforeseen consequences. N Engl J Med 2005; 353:414-416 (Pubitemid 41132348)
34. Berger JR. Natalizumab and progressive multifocal leucoencephalopathy. Ann Rheum Dis 2006; 65:48-53.
35. Suntharalingam G, Perry MR, Ward S, Brett SJ, Castello-Cortes A, Brunner MD, et al. Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N Engl J Med 2006; 355:1018-1028 (Pubitemid 44343545)
36. Kimby E. Tolerability and safety of rituximab (MabThera). Cancer Treat Rev 2005; 31:456-473
37. ICH S8. Immunotoxicity Studies for Human Pharmaceuticals. www.fda.gov/CBER/gdlns/ ichs8immuno.htm.
38. Cavagnaro JA. Preclinical safety evaluation of biopharmaceuticals: A science-based approach to facilitate clinical trials. Hoboken, NJ: Wiely 2008; 1033.
39. nd edition. Totowa, NJ: Humana Press 2004; 287-311.
40. Siegel EB. The Pre-Pre-IND FDA consultation process for nonclinical studies: Opportunities for launching a rapid drug or biologic development program. Preclinica 2004; 2:171-179
41. Clarke J, Hurst C, Martin P, Vahle J, Ponce R, Mounho B, et al. Duration of chronic toxicity studies for biotechnology-derived pharmaceuticals: Is 6 months still appropriate? Regul Toxicol Pharmacol 2008; 50:2-22.
42. ICH M3. Nonclinical Safety Studies for the Conduct of Human Clinical Trials for Pharmaceuticals. www.fda.gov/cder/Guidance/1855fnl.pdf.
43. Horvath C. Comparison of preclinical development programs for small molecules (Drug/ Pharmaceuticals) and large molecules (biologics/ Biopharmaceuticals): Studies, timing, materials and cost. In: Cavagnaro JA, Ed. Preclinical safety evaluation of biopharmaceuticals. Hoboken, NJ: Wiely 2008; 125-160
44. Cavagnaro J. Immunotoxicity assessment of biotechnology products: a regulatory point of view. Toxicology 1995; 105:1-6.
45. Brennan FR, Shaw L, Wing MG and Robinson C. Preclinical safety testing of biotechnology- derived pharmaceuticals. Mol Biotechnol 2004; 27:59-74.
46. FDA PTC. Points to Consider in the Manufacture and Testing of Monoclonal Antibody Products for Human Use. www.fda.gov/CBER/gdlns/ptc-mab.pdf.
47. 21CFR58. Good Laboratory Practice for Nonclinical Laboratory Studies. www.access.gpo. gov/nara/cfr/waisidx-03/21cfr58-03.html.
48. OECD GLP. Good Laboratory Practice www.oecd.org/department/0,3355,en- 2649-3438 1-1-1-1-1-1,00.html.
49. Estimating the Maximum Safe Starting Dose in Initial Clinical Trials for Therapeutics in Adult Healthy Volunteers. www.fda.gov/Cder/Guidance/5541fnl.pdf.
50. Strategies to identify and mitigate risks for first-in-human clinical trials with investigational medicinal products. http://www.emea.europa.eu/pdfs/ human/swp/2836707enfin.pdf.
51. nd ed. Humana Press 2004; Part III, 287-335.
52. ICH S3A. Toxicokinetics: the assessment of systemic exposure in toxicity studies www.fda.gov/CDER/GUIDANCE/ichs3a.pdf.
53. ICH S4. Duration of Chronic Toxicity Testing in Animals (Rodent and Non-Rodent Toxicity Testing. www.ich.org/LOB/media/MEDIA497.pdf.
54. ICH S7A. Safety pharmacology studies for human pharmaceuticals. www.ich.org/LOB/ media/MEDIA504.pdf.
55. ICH S7B. The Non-clinical Evaluation of the Potential for delayed Ventricular Repolarisation (QT Interval Prolongation) by Human Pharmaceuticals. www.ich.org/LOB/ media/MEDIA2192.pdf.
56. ICH S5(R2). Detection of Toxicity to Reproduction for Medicinal Products & Toxicity to Male Fertility. www.ich.org/LOB/media/MEDIA498.pdf.
57. ICH M4. Organisation of The Common Technical Document for The Registration of Pharmaceuticals for Human Use. www.ich.org/LOB/media/MEDIA554. pdf.
58. Position Paper on the non-clinical safety studies to support clinical trials with a single micro dose. www.emea.europa.eu/pdfs/human/swp/259902en.pdf.